Bristol-Myers Squibb
BMY
$71.09
Share price
-0.86%
Change (1 day)
19.46%
Change (1 year)
Categories
Market capitalization of Bristol-Myers Squibb (BMY)
Market cap: $151.79 Billion
As of October 2022 Bristol-Myers Squibb has a market cap of $151.79 Billion. This makes Bristol-Myers Squibb the world's 58th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Bristol-Myers Squibb from 2001 to 2022
End of year Market Cap
| Year | Market cap | Change |
|---|---|---|
| 2022 | $151.79 B | 9.68% |
| 2021 | $138.39 B | -1.27% |
| 2020 | $140.17 B | -1.99% |
| 2019 | $143.01 B | 69.42% |
| 2018 | $84.41 B | -15.83% |
| 2017 | $100.29 B | 2.69% |
| 2016 | $97.66 B | -14.52% |
| 2015 | $114.26 B | 17.1% |
| 2014 | $97.57 B | 11.88% |
| 2013 | $87.21 B | 64.19% |
| 2012 | $53.12 B | -11.04% |
| 2011 | $59.71 B | 32.73% |
| 2010 | $44.98 B | 4.26% |
| 2009 | $43.15 B | -6.24% |
| 2008 | $46.02 B | -12.08% |
| 2007 | $52.35 B | 1.38% |
| 2006 | $51.63 B | 14.83% |
| 2005 | $44.97 B | -9.84% |
| 2004 | $49.88 B | -10.1% |
| 2003 | $55.48 B | 22.68% |
| 2002 | $45.22 B | -54.81% |
| 2001 | $100.07 B |
End of Day market cap according to different sources
On Oct 2nd, 2022 the market cap of Bristol-Myers Squibb was reported to be:
$151.79 Billion
$151.79 Billion
$151.79 Billion
$151.79 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $429.50 B | 182.95% | 🇺🇸 USA |
 Novartis NVS | $166.30 B | 9.56% | 🇨🇭 Switzerland |
 Pfizer PFE | $245.59 B | 61.79% | 🇺🇸 USA |
 AbbVie ABBV | $237.29 B | 56.33% | 🇺🇸 USA |
 Eli Lilly LLY | $307.23 B | 102.40% | 🇺🇸 USA |
 Amgen AMGN | $120.57 B | -20.57% | 🇺🇸 USA |
 Sanofi SNY | $94.76 B | -37.57% | 🇫🇷 France |
 Biogen BIIB | $38.74 B | -74.48% | 🇺🇸 USA |
 Merck MRK | $218.16 B | 43.72% | 🇺🇸 USA |
 Astrazeneca AZN | $166.73 B | 9.84% | 🇬🇧 UK |